文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

I 期-III 期非小细胞肺癌的突变检测、治疗和生存：CancerLinQ Discovery 数据库回顾性分析。

mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.

机构信息

Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.

Global Oncology Outcome Research, AstraZeneca, Cambridge, UK.

出版信息

Future Oncol. 2024;20(28):2083-2096. doi: 10.1080/14796694.2024.2347826. Epub 2024 Jun 25.

DOI:10.1080/14796694.2024.2347826
PMID:38916211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11497985/
Abstract

To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC). Electronic records of USA-based patients in the CancerLinQ Discovery database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis. Of 3121 (21.6%) patients who had testing, 493 (15.8%) were mutation positive. Of 974 patients who underwent surgical resection, 513 (52.7%) received adjuvant therapy. A quarter of patients with mutation positive NSCLC received targeted adjuvant therapy. Approximately a fifth of patients underwent testing; biomarker testing is important to ensure optimal outcomes for patients with stage I-III NSCLC.

摘要

描述在美国癌症 LinQ 发现数据库中基于患者电子病历的 IA-IIIC 期非小细胞肺癌（NSCLC）的真实世界生物标志物检测、治疗和生存情况。对 2014 年至 2018 年间诊断为 IA-IIIC 期 NSCLC 的美国患者的数据库电子记录进行筛选；确定了一个经过审核的 14452 例记录的队列进行进一步分析。在 3121 名（21.6%）进行了 检测的患者中，有 493 名（15.8%）检测结果为阳性。在 974 名接受手术切除的患者中，有 513 名（52.7%）接受了辅助治疗。接受阳性 NSCLC 靶向辅助治疗的患者约占四分之一。大约五分之一的患者接受了 检测；对于 I-III 期 NSCLC 患者，生物标志物检测对于确保最佳治疗效果非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/69227ff9c3c7/IFON_A_2347826_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/d73605ffe32c/IFON_A_2347826_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/94012caae99a/IFON_A_2347826_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/11df1e8d1a8a/IFON_A_2347826_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/69227ff9c3c7/IFON_A_2347826_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/d73605ffe32c/IFON_A_2347826_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/94012caae99a/IFON_A_2347826_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/11df1e8d1a8a/IFON_A_2347826_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd31/11497985/69227ff9c3c7/IFON_A_2347826_F0004_C.jpg

相似文献

[1]
mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.

Future Oncol. 2024

[2]
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.

JAMA Netw Open. 2021-11-1

[3]
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.

Target Oncol. 2022-5

[4]
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Lancet Oncol. 2017-11-21

[5]
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.

Lung Cancer. 2022-11

[6]
The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.

Pathol Oncol Res. 2021

[7]
Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.

N Engl J Med. 2024-8-15

[8]
EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.

Cancer Treat Res Commun. 2024

[9]
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

N Engl J Med. 2020-9-19

[10]
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

J Clin Oncol. 2023-4-1

引用本文的文献

[1]
Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023.

Front Oncol. 2024-7-31

本文引用的文献

[1]
Sex Differences in Lung Cancer.

Cancers (Basel). 2023-6-8

[2]
Overall Survival with Osimertinib in Resected -Mutated NSCLC.

N Engl J Med. 2023-7-13

[3]
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Ann Oncol. 2023-4

[4]
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

J Clin Oncol. 2023-4-1

[5]
Sex differences in the characteristics and survival of patients with non-small-cell lung cancer: A retrospective analytical study based on real-world clinical data of the Korean population.

Thorac Cancer. 2022-9

[6]
Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World.

Front Oncol. 2022-6-29

[7]
Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark.

Cancer Med. 2023-1

[8]
Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data.

Drugs Real World Outcomes. 2022-9

[9]
Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort.

J Thorac Oncol. 2022-5

[10]
Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.

Cancer Epidemiol. 2022-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索